Dr. Santomasso on Managing CNS Toxicity from CAR T-Cell Therapy for B-Cell Lymphoma

Video

Bianca D. Santomasso, MD, PhD, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.

Bianca D. Santomasso, MD, PhD, assistant attending neurologist, Memorial Sloan Kettering Cancer Center, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.

Santomasso and her colleagues perform the Immune Effector Cell Encephalopathy (ICE) screening at least once daily on patients who have received CAR T-cell therapy. The perfect score on ICE is 10 and when a patient's score drops to 9, they start to be monitored more closely.

Severe cases of neurotoxicity can progress beyond language and disorientation to seizures and even falling into a coma, explains Santomasso. When patients have severe toxicity, they are given corticosteroids. Santomasso is unsure how the corticosteroids reverse the toxicity, but she believes they prevent the most severe progression as the toxicity runs its course. Some patients spontaneously recover without steroids, but corticosteroids are usually given to be safe. In Santomasso’s experience, giving corticosteroids has not changed the efficacy of treatment, though it is a subject being actively researched.

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.